Pubblicazioni
scientifiche

I nostri ricercatori contribuiscono al progresso della conoscenza scientifica attraverso pubblicazioni realizzate insieme ai centri e alle università con cui collaboriamo in tutto il mondo.

Journal of patient-reported outcomes maggio 2020

Development of the Neurotrophic Keratopathy Questionnaire: Qualitative Research

L.T. Murray

Immunity maggio 2020

CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps That Interfere With Immune Cytotoxicity

Á. Teijeira et al.

International Journal of Molecular Sciences aprile 2020

Combining Molecular Dynamics and Docking Simulations to Develop Targeted Protocols for Performing Optimized Virtual Screening Campaigns on The hTRPM8 Channel

C. Talarico et al.

Current pharmaceutical design marzo 2020

Focus on the use of Resveratrol as adjuvant in glioblastoma therapy

Dionigi L et al.

Biomedicine & Pharmacotherapy marzo 2020

Inhibition of osteoclast activity by complement regulation with DF3016A, a novel small-molecular-weight C5aR inhibitor

R D'Angelo et al.

Nature febbraio 2020

Topical recombinant human Nerve growth factor (rh-NGF) is neuroprotective to retinal ganglion cells by targeting secondary degeneration

Guo, L., Davis, B.M., Ravindran, N. et al.

Aging gennaio 2020

Autocrine CXCL8-dependent invasiveness triggers modulation of actin cytoskeletal network and cell dynamics

A Antonosante et al.

Ophthalmology gennaio 2020

Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial

SC Pflugfelder et al.

The British journal of ophthalmology gennaio 2020

Effect of Recombinant Human Nerve Growth Factor Eye Drops in Patients With Dry Eye: A Phase IIa, Open Label, Multiple-Dose Study

M Sacchetti et al.

Diabetes Care gennaio 2020

Targeting CXCR1/2 does not improve insulin secretion after pancreatic islet transplantation: A phase 3, double-blind, randomized, placebo-controlled trial in type 1 diabetes

Paola Maffi et al.

Dompé farmaceutici S.p.A. Socio Unico / Capitale sociale € 50.000.000,00
REA MI 289519 - Registro Imprese di Milano / Codice Fiscale e Partita IVA (VAT) IT00791570153

Chiudi